Provider of virtual health care services, including telehealth visits, chronic condition management and mental health care.
Provider of virtual health care services, including telehealth visits, chronic condition management and mental health care.
Integrated Care is sold to employers and health plans for a fixed monthly fee per enrolled member, with extra charges per visit, while BetterHelp sells therapy subscriptions straight to consumers who pay out of pocket and are won through heavy online advertising.
Moat: narrow (scale, brand, data). Large telehealth user base and employer/health-plan contracts, though facing intensifying low-cost competition.
Headquarters: Purchase, New York · Founded: 2002 · Employees: 5,600
Size Teladoc Health (TDOC) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.47B, the 1983rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.06 on 18 Nov 2026.
Performance Over six months the shares gained 24.4%, against +14.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 2.4% over the last twelve months (peer median +9.2%); the operating margin is -5.4% (peer median 6.2%).
Valuation It trades at 0.7× enterprise value to sales against a peer median of 2.0× (3rd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -25 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.2 points below its cost of capital (11.2% WACC).
Credit Teladoc Health has 1 bond outstanding ($1.00B).
Short interest Short interest is 17.7% of the free float (30 Oct 2026).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.47B | $2.53B | $2.57B | $2.60B | $2.41B |
| Revenue growth | — | -2% | -1% | +8% | — |
| Gross profit | $1.32B | $1.39B | $1.44B | $1.51B | $1.41B |
| EBITDA | $246M | $213M | $174M | $141M | $43.3M |
| Net income | -$155M | -$200M | -$1.00B | -$220M | -$13.7B |
| Free cash flow | $262M | $281M | $283M | $339M | $173M |
| Capital expenditure | $142M | $157M | $124M | $156M | $173M |
| Total debt | $1.04B | $1.04B | $1.58B | $1.59B | $1.59B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Teladoc Health TDOC | $1.47B | +24% | -2% | -5% | 0.7× | -6.4% |
| Hims & Hers Health HIMS | $4.00B | -26% | +30% | -1% | 1.7× | n/a |
| CVS Health CVS | $104B | -13% | +7% | 4% | 0.4× | -3.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TDOC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +29.8% | -0.3% | 2nd highest of 21 |
| 6-month return | +24.4% | +14.0% | 8th highest of 21 |
| Distance from 52-week high | -18.5% | -23.8% | 8th highest of 21 |
| Revenue growth (TTM) | -2.4% | +9.2% | 5th lowest of 21 |
| Operating margin | -5.4% | 6.2% | 5th lowest of 21 |
| EV / Sales | 0.7× | 2.0× | 3rd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | -6.4% | 8.5% | 2nd least demanding of 15 |
| Growth delivered (Del g) | +18.3% | +9.5% | 5th highest of 15 |
| Hurdle (Req g minus delivered) | -24.6 pp | +6.7 pp | 2nd least demanding of 15 |
| ROIC minus cost of capital | -18.2 pp | -3.6 pp | 4th lowest of 20 |
| EV / EBITDA | 6.7× | 20.0× | 2nd cheapest of 14 |
| Net debt / EBITDA | 0.8× | 2.8× | 6th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | 0.7× | -6.4% | +18.3% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 1.0× | 9.7% | +2.1% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 2.6× | 18.8% | +13.0% |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 0.2× | n/a | n/a |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 3.5× | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 0.4× | 3.5% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 1.7× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | 4.8× | n/a | n/a |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 2.1× | n/a | n/a |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | 18.2× | n/a | n/a |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 1.6× | 6.8% | +6.5% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 17.5× | 40.4% | +16.7% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 2.5× | 7.3% | +18.9% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 1.4× | 0.3% | -1.1% |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 1.5× | 20.7% | +19.4% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | 2.8× | n/a | n/a |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 6.5× | 32.4% | +10.5% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | 1.6× | 21.2% | +8.5% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 1.8× | -18.0% | +253.5% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 1.9× | 5.4% | -6.1% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 7.8× | 43.0% | +26.9% |
Teladoc Health has 1 bond outstanding with $1.00B face value.